Add to watchlist
€6.78
Last updated:06/09/2021
135A: F
SCYNEXIS, Inc

SCYNEXIS, Inc., a biotechnology company, delivers therapies for the treatment fungal infections in the United States. It is developing its lead product candidate, ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including vulvovagina… Show more

P/E ratio
-

Stock volatility (Beta)
past 12 months

Become our supporter to unlock all data!
Company results
Quarterly
Annual
Fundamentals
2017
2018
2019
2020
Net Income
Income minus expenses, depreciation, interest, taxes, and other expenses
-25.06M
-12.468M
+50.25%
-53.71M
-330.78%
-55.185M
-2.75%
Cashflow
Sum up money going in and out company
-24.556M
-28.323M
-15.34%
-38.119M
-34.59%
-49.354M
-29.47%
Total liabilities
All combined debts and obligations
24.44M
21.945M
-10.21%
44.258M
+101.68%
79.778M
+80.26%
Company profile
CEO
Dr. Marco Taglietti
Market capitalization
Micro (137.75M)